关键词: font-size:13.3333px, ">达沙替尼；儿童费城染色体阳性急性淋巴细胞白血病；药品临床综合评价；方法学

Abstract: Objective： To evaluate the clinical value of dasatinib in the treatment of children with Philadelphia-positive acute lymphoblastic leukemia， and to provide basis for drug label revision and rational drug selection in clinic. Methods： Literature review， retrospective cohort study and pharmacoeconomic model were used to compare the efficacy， safety and economy of dasatinib and imatinib in the treatment of children with Philadelphia-positive acute lymphoblastic leukemia. Results： The efficacy of dasatinib treatment was superior to imatinib. The dasatinib had also the potential economic advantages and there was no significant difference in safety. Conclusion： Dasatinib is superior to imatinib in efficacy and economy， and there is no significant difference in safety. Therefore， it is recommended for the clinical treatment of children with pH + ALL. Although multi-dimensional evidences were collected in this evaluation， the quantity and quality of evidences were not enough， and the conclusions needed to be verified in a larger scope. In the next step， multi-center real world studies could be carried out to rigorously demonstrate the clinical value of relevant drugs and provide evidence for drug policy formulation.
  

Key words: font-size:13.3333px, ">Dasatinib； Philadelphia-positive acute lymphoblastic leukemia in children； Drug clinical comprehensive evaluation； Methodology